Phase 1 Study to Determine the Safety and Immunogenicity of a Sublingual Administration of NSV0001 in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2017
At a glance
- Drugs NSV 0001 (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Nitto Denko
- 14 Sep 2017 Status changed from active, no longer recruiting to completed.
- 28 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Nov 2016 New trial record